HALO - Halozyme Therapeutics - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

HALO is currently covered by 9 analysts with an average price target of $66.79. This is a potential upside of $6.57 (10.91%) from yesterday's end of day stock price of $60.22.

Halozyme Therapeutics's activity chart (see below) currently has 144 price targets and 147 ratings on display. The stock rating distribution of HALO is 82.26% BUY and 17.74% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 88.23% with an average time for these price targets to be met of 279.16 days.

Highest price target for HALO is $75, Lowest price target is $44, average price target is $59.

Most recent stock forecast was given by MITCHELL KAPOOR from HC WAINWRIGHT on 06-Mar-2025. First documented stock forecast 02-Aug-2012.

Currently out of the existing stock ratings of HALO, 51 are a BUY (82.26%), 11 are a HOLD (17.74%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$72

1 months 7 days ago
(06-Mar-2025)

20/28 (71.43%)

$14.23 (24.63%)

197

Buy

$75

$14.78 (24.54%)

$60

1 months 24 days ago
(20-Feb-2025)

4/6 (66.67%)

$17.56 (30.57%)

109

Hold

$57

$-3.22 (-5.35%)

$58

3 months ago
(13-Jan-2025)

7/7 (100%)

$2.86 (5.28%)

273

Hold

$53

$-7.22 (-11.99%)

$52

3 months 3 days ago
(10-Jan-2025)

15/15 (100%)

$0.2 (0.38%)

131

Buy

$73

$12.78 (21.22%)

$71

5 months 12 days ago
(01-Nov-2024)

6/12 (50%)

$15.85 (27.73%)

312

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is HALO (Halozyme Therapeutics) average time for price targets to be met?

On average it took 279.16 days on average for the stock forecasts to be realized with a an average price target met ratio 88.23

Which analyst has the current highest performing score on HALO (Halozyme Therapeutics) with a proven track record?

VIKRAM PUROHIT

Which analyst has the most public recommendations on HALO (Halozyme Therapeutics)?

Vikram Purohit works at MORGAN STANLEY and has 5 price targets and 1 ratings on HALO

Which analyst is the currently most bullish on HALO (Halozyme Therapeutics)?

Geoffrey Porges with highest potential upside - $16.84

Which analyst is the currently most reserved on HALO (Halozyme Therapeutics)?

Eun Yang with lowest potential downside - -$47.22

Halozyme Therapeutics in the News

European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility

Subcutaneous DARZALEX® is co-formulated with Halozyme’s ENHANZE® drug delivery technology SAN DIEGO, April 9, 2025 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Janssen-Cilag International NV, a Johnson & Johnson company, received European Commission (EC) approval for an indication extension of DARZALEX® (daratumumab) subcutaneous (SC) co-formulated with ENHANZE®in the frontline setting. The...

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. While you may have an investing style you rely on, finding great stocks is made easier with the Zacks Style Scores. These are complementary indicators that rate stocks based on value, growth, and/or momentum characteristics. Why...

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?